Preoperatív kemoterápia a colorectalis májáttétes betegek sebészi kezelésében.

Translated title of the contribution: [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].

Kristóf Dede, I. Láng, Balázs Pörneczi, G. Mester, András Fekete, György Koszegi, Tamás Mersich, István Besznyák, Attila Bursics

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The only curative treatment of colorectal liver metastases (CRLM) is surgical resection. Preoperative/neoadjuvant chemotherapy can be used for resectable, for borderline resectable or even for irresectable CRLM patients. Data of CRLM patients treated with surgical resection at the Uzsoki Hospital were analysed. Patients were classified into two groups, (A) who received preoperative chemotherapy before hepatic resection, and (B) who received no chemotherapy before resection. Between 01.01.2007. and 31.12.2010. 128 CRLM patients were treated with hepatic resection. 68 patients (53%) received chemotherapy before hepatic resection, 60 patients (47%) were resected without neoadjuvant chemotherapy. There was no significant difference in the complications between the groups (p = 0.39). Median overall survival was 41 months. The progression free survival (PFS) at 3 and 5 years were 25%, the 3 and 5 year overall survival (OS) were 55% and 31%. Both PFS and OS were significantly worse in the chemotherapy group (p = 0.014, p = 0.015). The subgroup of patients receiving bevacizumab containing preoperative chemotherapy has significanly better PFS than patients receiving only cytotoxic chemotherapy (p = 0.004). Surgical resection of CRLM patients results good survival data even in non-selected patients, although the very long survival results reported in the literature couldn't have been reproduced in this patient population. When preoperative chemotherapy was combined with bevacizumab, survival was similar to the upfront resected patients.

Original languageHungarian
Pages (from-to)325-330
Number of pages6
JournalMagyar sebészet
Volume66
Issue number6
Publication statusPublished - Dec 2013

Fingerprint

Neoplasm Metastasis
Drug Therapy
Liver
Survival
Therapeutics
Disease-Free Survival
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dede, K., Láng, I., Pörneczi, B., Mester, G., Fekete, A., Koszegi, G., ... Bursics, A. (2013). Preoperatív kemoterápia a colorectalis májáttétes betegek sebészi kezelésében. Magyar sebészet, 66(6), 325-330.

Preoperatív kemoterápia a colorectalis májáttétes betegek sebészi kezelésében. / Dede, Kristóf; Láng, I.; Pörneczi, Balázs; Mester, G.; Fekete, András; Koszegi, György; Mersich, Tamás; Besznyák, István; Bursics, Attila.

In: Magyar sebészet, Vol. 66, No. 6, 12.2013, p. 325-330.

Research output: Contribution to journalArticle

Dede, K, Láng, I, Pörneczi, B, Mester, G, Fekete, A, Koszegi, G, Mersich, T, Besznyák, I & Bursics, A 2013, 'Preoperatív kemoterápia a colorectalis májáttétes betegek sebészi kezelésében.', Magyar sebészet, vol. 66, no. 6, pp. 325-330.
Dede, Kristóf ; Láng, I. ; Pörneczi, Balázs ; Mester, G. ; Fekete, András ; Koszegi, György ; Mersich, Tamás ; Besznyák, István ; Bursics, Attila. / Preoperatív kemoterápia a colorectalis májáttétes betegek sebészi kezelésében. In: Magyar sebészet. 2013 ; Vol. 66, No. 6. pp. 325-330.
@article{4485276633774a649b71a47ed311ef64,
title = "Preoperat{\'i}v kemoter{\'a}pia a colorectalis m{\'a}j{\'a}tt{\'e}tes betegek seb{\'e}szi kezel{\'e}s{\'e}ben.",
abstract = "The only curative treatment of colorectal liver metastases (CRLM) is surgical resection. Preoperative/neoadjuvant chemotherapy can be used for resectable, for borderline resectable or even for irresectable CRLM patients. Data of CRLM patients treated with surgical resection at the Uzsoki Hospital were analysed. Patients were classified into two groups, (A) who received preoperative chemotherapy before hepatic resection, and (B) who received no chemotherapy before resection. Between 01.01.2007. and 31.12.2010. 128 CRLM patients were treated with hepatic resection. 68 patients (53{\%}) received chemotherapy before hepatic resection, 60 patients (47{\%}) were resected without neoadjuvant chemotherapy. There was no significant difference in the complications between the groups (p = 0.39). Median overall survival was 41 months. The progression free survival (PFS) at 3 and 5 years were 25{\%}, the 3 and 5 year overall survival (OS) were 55{\%} and 31{\%}. Both PFS and OS were significantly worse in the chemotherapy group (p = 0.014, p = 0.015). The subgroup of patients receiving bevacizumab containing preoperative chemotherapy has significanly better PFS than patients receiving only cytotoxic chemotherapy (p = 0.004). Surgical resection of CRLM patients results good survival data even in non-selected patients, although the very long survival results reported in the literature couldn't have been reproduced in this patient population. When preoperative chemotherapy was combined with bevacizumab, survival was similar to the upfront resected patients.",
author = "Krist{\'o}f Dede and I. L{\'a}ng and Bal{\'a}zs P{\"o}rneczi and G. Mester and Andr{\'a}s Fekete and Gy{\"o}rgy Koszegi and Tam{\'a}s Mersich and Istv{\'a}n Beszny{\'a}k and Attila Bursics",
year = "2013",
month = "12",
language = "Hungarian",
volume = "66",
pages = "325--330",
journal = "Magyar Sebeszet",
issn = "0025-0295",
publisher = "Ifjusagi Lapkiado Vallalat",
number = "6",

}

TY - JOUR

T1 - Preoperatív kemoterápia a colorectalis májáttétes betegek sebészi kezelésében.

AU - Dede, Kristóf

AU - Láng, I.

AU - Pörneczi, Balázs

AU - Mester, G.

AU - Fekete, András

AU - Koszegi, György

AU - Mersich, Tamás

AU - Besznyák, István

AU - Bursics, Attila

PY - 2013/12

Y1 - 2013/12

N2 - The only curative treatment of colorectal liver metastases (CRLM) is surgical resection. Preoperative/neoadjuvant chemotherapy can be used for resectable, for borderline resectable or even for irresectable CRLM patients. Data of CRLM patients treated with surgical resection at the Uzsoki Hospital were analysed. Patients were classified into two groups, (A) who received preoperative chemotherapy before hepatic resection, and (B) who received no chemotherapy before resection. Between 01.01.2007. and 31.12.2010. 128 CRLM patients were treated with hepatic resection. 68 patients (53%) received chemotherapy before hepatic resection, 60 patients (47%) were resected without neoadjuvant chemotherapy. There was no significant difference in the complications between the groups (p = 0.39). Median overall survival was 41 months. The progression free survival (PFS) at 3 and 5 years were 25%, the 3 and 5 year overall survival (OS) were 55% and 31%. Both PFS and OS were significantly worse in the chemotherapy group (p = 0.014, p = 0.015). The subgroup of patients receiving bevacizumab containing preoperative chemotherapy has significanly better PFS than patients receiving only cytotoxic chemotherapy (p = 0.004). Surgical resection of CRLM patients results good survival data even in non-selected patients, although the very long survival results reported in the literature couldn't have been reproduced in this patient population. When preoperative chemotherapy was combined with bevacizumab, survival was similar to the upfront resected patients.

AB - The only curative treatment of colorectal liver metastases (CRLM) is surgical resection. Preoperative/neoadjuvant chemotherapy can be used for resectable, for borderline resectable or even for irresectable CRLM patients. Data of CRLM patients treated with surgical resection at the Uzsoki Hospital were analysed. Patients were classified into two groups, (A) who received preoperative chemotherapy before hepatic resection, and (B) who received no chemotherapy before resection. Between 01.01.2007. and 31.12.2010. 128 CRLM patients were treated with hepatic resection. 68 patients (53%) received chemotherapy before hepatic resection, 60 patients (47%) were resected without neoadjuvant chemotherapy. There was no significant difference in the complications between the groups (p = 0.39). Median overall survival was 41 months. The progression free survival (PFS) at 3 and 5 years were 25%, the 3 and 5 year overall survival (OS) were 55% and 31%. Both PFS and OS were significantly worse in the chemotherapy group (p = 0.014, p = 0.015). The subgroup of patients receiving bevacizumab containing preoperative chemotherapy has significanly better PFS than patients receiving only cytotoxic chemotherapy (p = 0.004). Surgical resection of CRLM patients results good survival data even in non-selected patients, although the very long survival results reported in the literature couldn't have been reproduced in this patient population. When preoperative chemotherapy was combined with bevacizumab, survival was similar to the upfront resected patients.

UR - http://www.scopus.com/inward/record.url?scp=84899617565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899617565&partnerID=8YFLogxK

M3 - Article

C2 - 24333977

AN - SCOPUS:84899617565

VL - 66

SP - 325

EP - 330

JO - Magyar Sebeszet

JF - Magyar Sebeszet

SN - 0025-0295

IS - 6

ER -